Research Paper Volume 13, Issue 16 pp 20661—20683

METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas

Experimental examination of METTL21B expression and prognosis analysis in LGG patient clinical samples. (A) The relative mRNA expression level in LGG with different WHO grades. (B) Representative immunohistochemistry images for METTL21B in LGG with different WHO grades. Positive cells showed nuclear and/or cytoplasmic brown staining while negative cells showed blue nuclei counter staining. (C) METTL21B positive cells were counted in LGG with different WHO grades. *PD, E) METTL21B high expression predicts a worse progression-free and overall survival (P

Figure 3. Experimental examination of METTL21B expression and prognosis analysis in LGG patient clinical samples. (A) The relative mRNA expression level in LGG with different WHO grades. (B) Representative immunohistochemistry images for METTL21B in LGG with different WHO grades. Positive cells showed nuclear and/or cytoplasmic brown staining while negative cells showed blue nuclei counter staining. (C) METTL21B positive cells were counted in LGG with different WHO grades. *P<0.05; **P<0.01; ns: no significance. (D, E) METTL21B high expression predicts a worse progression-free and overall survival (P<0.001 and P<0.01, respectively).